The first patient in the trial has begun treatment with the novel, potential first-in-class B7-H3 directed antibody-drug conjugate (ADC). 1,2 “Patients with metastatic esophageal squamous cell ...

Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around 7 to 8. This is much higher than the DAR’s of older generations of ADCs, which ...

A new solution methodology for the constant matrix, decoupled power flow problem is presented in this paper. The proposed method uses the conjugate gradient method instead of the traditional direct ...

The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has expanded age-based recommendations for pneumococcal conjugate vaccines (PCVs), with a ...

MSD has received approval from the European Commission (EC) for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia due to Streptococcus pneumoniae ...

In this issue of The Lancet Oncology, another phase 2 trial conducted exclusively in China with a different HER2-targeted antibody–drug conjugate as the palliative second-line treatment of NSCLC is ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical tr ...

In late December, Ideaya licensed rights from Jiangsu Hengrui to develop SHR-4849, a DLL3-targeted antibody–drug conjugate (ADC), which delivers a toxic payload to cancer cells.

KYM901 is a multicentre, open-label, single-arm, phase 1 trial consisting of dose-escalation and dose-expansion stages. Patients with advanced solid tumours, including gastric or gastro-oesophageal ...

HDP-101, a novel investigational B-cell maturation antigen (BCMA)–targeting antibody-drug conjugate (ADC), demonstrated encouraging efficacy in patients with progressive or refractory multiple ...